Ahmed Zakari

Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Josep M. Llovet, Masatoshi Kudo, Philippe Merle et al. · The Lancet Oncology · 2023 · 421 citations · Full text

Medicine, Oncology, Pharmacology +12

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study

Philip A. Philip, Jill Lacy, Fabienne Portales et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 246 citations

Medicine, Oncology, Pharmacology +10

Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Margaret A. Tempero, Uwe Pelzer, Eileen M. O’Reilly et al. · Journal of Clinical Oncology · 2022 · 132 citations · Full text

Medicine, Oncology, Pharmacology +13

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment

Jeremiah L. Oyer, Veethika Pandey, Robert Y. Igarashi et al. · Cytotherapy · 2016 · 86 citations · Full text

Life Sciences, Immunology, Oncology +14

Generation of Highly Cytotoxic Natural Killer Cells for Treatment of Acute Myelogenous Leukemia Using a Feeder-Free, Particle-Based Approach

Jeremiah L. Oyer, Robert Y. Igarashi, Alexander R. Kulikowski et al. · Biology of Blood and Marrow Transplantation · 2015 · 74 citations · Full text

Medicine, Immunology, Oncology +15